UPDATE 1-U.S. FDA panel backs claim Lilly diabetes drug cuts cardiac death

June 28 (Reuters) - Eli Lilly & Co and Boehringer Ingelheim should be allowed to claim that their diabetes drug Jardiance cuts the risk of cardiovascular death, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday.